US 6,638,764 B2 · Methods of inhibiting phagocytosis

Abstract

The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.

Claims4

Dependent claims

A method of inhibiting the phagocytic potential of a cell comprising introducing into said cell FcγRIIB in an amount such that said inhibition is effected.

Dependencies are inferred from the claim text.

Facts

Application

09/811,492Filed 20 Mar 2001 · continuation

Priority

30 Sep 1993

Published

US 2002/0068703 A16 Jun 2002

Granted

28 Oct 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C12N 15/1137
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against enzymes
A61K 38/07
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tetrapeptides
C07K 14/70535
Immunoglobulin superfamily: fc-receptors, e.g. CD16, CD32, CD64
A61K 38/00
Medicinal preparations containing peptides

Family

Application08/129,381Parent of this continuation-in-part · filed 30 Sep 1993

Application08/316,425Parent of this continuation-in-part · filed 30 Sep 1994

Application08/483,530Parent of this continuation-in-part · filed 7 Jun 1995

Application08/657,884Parent of this continuation · filed 7 Jun 1996

Application09/158,980Parent of this continuation · filed 14 Sep 1998

US 2002/0068703 A1Pre-grant publication · published 6 Jun 2002

US 6,242,427 B1Parent of this continuation

US 5,858,981 AParent of this continuation

Application08/657,884Parent of this continuation-in-part

US 6,638,764 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

09/811,492Filed 20 Mar 2001 · continuation

Priority

30 Sep 1993

Published

US 2002/0068703 A16 Jun 2002

Granted

28 Oct 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C12N 15/1137
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against enzymes
A61K 38/07
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tetrapeptides
C07K 14/70535
Immunoglobulin superfamily: fc-receptors, e.g. CD16, CD32, CD64
A61K 38/00
Medicinal preparations containing peptides

Family

Application08/129,381Parent of this continuation-in-part · filed 30 Sep 1993

Application08/316,425Parent of this continuation-in-part · filed 30 Sep 1994

Application08/483,530Parent of this continuation-in-part · filed 7 Jun 1995

Application08/657,884Parent of this continuation · filed 7 Jun 1996

Application09/158,980Parent of this continuation · filed 14 Sep 1998

US 2002/0068703 A1Pre-grant publication · published 6 Jun 2002

US 6,242,427 B1Parent of this continuation

US 5,858,981 AParent of this continuation

Application08/657,884Parent of this continuation-in-part

US 6,638,764 B2This patent

From the US filing history. Foreign family members aren’t listed.

Methods of inhibiting phagocytosis

Life of this patent

Abstract

Claims4

Methods of inhibiting phagocytosis

Life of this patent

Abstract

Claims4